MedTrace Logo

Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease

NCT05294887 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2022-03-24

No results posted yet for this study

Summary

EXAMINE-CAD-DZHK22 is a prospective, randomized, double-blind, placebo-controlled, crossover trial investigating the efficacy of beta blocker (bisoprolol) and calcium channel blocker (diltiazem) therapy in symptomatic patients with non-obstructed coronary arteries according to coronary physiological testing results.

Conditions

  • Coronary Microvascular Dysfunction
  • Microvascular Angina
  • Vasospasm, Coronary
  • Vasospastic Angina
  • Prinzmetal Angina
  • Coronary Artery Disease

Interventions

DRUG

Bisoprolol

beta-adrenergic receptor blocker

DRUG

Diltiazem

calcium channel blocker

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Ulf Landmesser, Prof. Dr. · Charité University, Berlin, Germany

  • Barbara E Stähli, Prof. Dr. · Universitätsspital Zürich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294887 on ClinicalTrials.gov